Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
24 10 2023
24 10 2023
Historique:
received:
06
02
2023
accepted:
21
06
2023
medline:
6
11
2023
pubmed:
2
9
2023
entrez:
1
9
2023
Statut:
ppublish
Résumé
In a proportion of patients, dementia with Lewy bodies (DLB) is associated with Alzheimer disease (AD) copathology, which is linked to accelerated cognitive decline and more extensive cortical atrophy. The objective was to evaluate the relationship between a biomarker of AD copathology, plasma tau phosphorylated at residue 181 (ptau181), and the treatment effects of the p38α kinase inhibitor neflamapimod, which targets the cholinergic degenerative process in DLB. The AscenD-LB study was a phase 2a, randomized (1:1), 16-week, placebo-controlled clinical trial of neflamapimod in DLB, the main results of which have been published. After the study was completed (i.e., post hoc), pretreatment plasma ptau181 levels were determined and participants were grouped based on a cutoff for AD pathology of 2.2 pg/mL (established in a separate cohort to identify AD from healthy controls). Clinical outcomes for the comparison of placebo with neflamapimod 40 mg three times daily (TID; the higher and more clinically active of 2 doses studied) were analyzed using mixed models for repeated measures within each subgroup (baseline plasma ptau181 < and ≥2.2 pg/mL). Pretreatment plasma ptau181 levels were determined in eighty-five participants with mild-to-moderate DLB receiving cholinesterase inhibitors, with 45 participants below and 40 above the 2.2 pg/mL cutoff at baseline. In the 16-week treatment period, in the comparison of placebo with neflamapimod 40 mg TID, for all end points evaluated, improvements with neflamapimod treatment were greater in participants below the cutoff, compared with those above the cutoff. In addition, participants below the ptau181 cutoff at baseline showed significant improvement over placebo in an attention composite measure (+0.42, 95% CI 0.07-0.78, Exclusion of patients with elevated plasma ptau181, potentially through excluding patients with extensive cortical neurodegeneration, enriches for a patient with DLB population that is more responsive to neflamapimod. More generally, plasma biomarkers of AD copathology at study entry should be considered as stratification variables in DLB clinical trials. NCT04001517 at ClinicalTrials.gov.
Sections du résumé
BACKGROUND AND OBJECTIVES
In a proportion of patients, dementia with Lewy bodies (DLB) is associated with Alzheimer disease (AD) copathology, which is linked to accelerated cognitive decline and more extensive cortical atrophy. The objective was to evaluate the relationship between a biomarker of AD copathology, plasma tau phosphorylated at residue 181 (ptau181), and the treatment effects of the p38α kinase inhibitor neflamapimod, which targets the cholinergic degenerative process in DLB.
METHODS
The AscenD-LB study was a phase 2a, randomized (1:1), 16-week, placebo-controlled clinical trial of neflamapimod in DLB, the main results of which have been published. After the study was completed (i.e., post hoc), pretreatment plasma ptau181 levels were determined and participants were grouped based on a cutoff for AD pathology of 2.2 pg/mL (established in a separate cohort to identify AD from healthy controls). Clinical outcomes for the comparison of placebo with neflamapimod 40 mg three times daily (TID; the higher and more clinically active of 2 doses studied) were analyzed using mixed models for repeated measures within each subgroup (baseline plasma ptau181 < and ≥2.2 pg/mL).
RESULTS
Pretreatment plasma ptau181 levels were determined in eighty-five participants with mild-to-moderate DLB receiving cholinesterase inhibitors, with 45 participants below and 40 above the 2.2 pg/mL cutoff at baseline. In the 16-week treatment period, in the comparison of placebo with neflamapimod 40 mg TID, for all end points evaluated, improvements with neflamapimod treatment were greater in participants below the cutoff, compared with those above the cutoff. In addition, participants below the ptau181 cutoff at baseline showed significant improvement over placebo in an attention composite measure (+0.42, 95% CI 0.07-0.78,
DISCUSSION
Exclusion of patients with elevated plasma ptau181, potentially through excluding patients with extensive cortical neurodegeneration, enriches for a patient with DLB population that is more responsive to neflamapimod. More generally, plasma biomarkers of AD copathology at study entry should be considered as stratification variables in DLB clinical trials.
TRIAL REGISTRATION INFORMATION
NCT04001517 at ClinicalTrials.gov.
Identifiants
pubmed: 37657939
pii: WNL.0000000000207755
doi: 10.1212/WNL.0000000000207755
pmc: PMC10624490
doi:
Substances chimiques
Biomarkers
0
Cholinesterase Inhibitors
0
Protein Kinase Inhibitors
0
Banques de données
ClinicalTrials.gov
['NCT04001517']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1708-e1717Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Neuropsychopharmacology. 2022 Jan;47(1):405-406
pubmed: 34389810
J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):113-118
pubmed: 27794030
Brain Commun. 2022 Feb 07;4(2):fcac013
pubmed: 35415608
Brain Res. 2006 Aug 9;1104(1):153-9
pubmed: 16828061
Dement Geriatr Cogn Disord. 2004;17 Suppl 1:3-14
pubmed: 14676464
Brain. 2022 Jun 3;145(5):1773-1784
pubmed: 34605858
Mov Disord. 2021 Mar;36(3):767-771
pubmed: 33285015
Brain. 2012 Aug;135(Pt 8):2470-7
pubmed: 22810436
Int J Geriatr Psychiatry. 2006 Aug;21(8):755-60
pubmed: 16906631
Alzheimers Res Ther. 2021 Dec 4;13(1):198
pubmed: 34863295
JAMA Netw Open. 2019 Dec 2;2(12):e1916439
pubmed: 31790563
Expert Rev Neurother. 2008 Nov;8(11):1703-18
pubmed: 18986241
Neurology. 2022 Mar 22;98(12):e1262-e1272
pubmed: 35074893
Transl Psychiatry. 2020 Aug 3;10(1):267
pubmed: 32747635
Neuroimage Clin. 2021;30:102604
pubmed: 33711623
Arch Phys Med Rehabil. 2013 Jul;94(7):1300-5
pubmed: 23473700
J Neurol Neurosurg Psychiatry. 1998 May;64(5):653-6
pubmed: 9598683
J Prev Alzheimers Dis. 2021;8(2):151-160
pubmed: 33569561
Alzheimers Res Ther. 2021 Mar 29;13(1):69
pubmed: 33781319
Front Neurol. 2021 Sep 07;12:695696
pubmed: 34557143
J Neurol. 2014 Oct;261(10):1939-48
pubmed: 25059393
Arch Clin Neuropsychol. 2011 Aug;26(5):412-24
pubmed: 21613302
Mov Disord. 2022 Jun;37(6):1256-1264
pubmed: 35261094
Neuroimage Clin. 2020;27:102333
pubmed: 32674011
JAMA Neurol. 2022 Jan 1;79(1):32-37
pubmed: 34807233
Front Neural Circuits. 2022 May 31;16:916499
pubmed: 35712645
Neuroimage Clin. 2020;28:102504
pubmed: 33395993
Brain Res. 2004 Oct 1;1022(1-2):101-9
pubmed: 15353219
Neuroimage Clin. 2020;26:102196
pubmed: 32059167
JAMA Neurol. 2021 Apr 1;78(4):396-406
pubmed: 33427873
Front Digit Health. 2021 Nov 03;3:750549
pubmed: 34806078
Neurology. 2022 Mar 1;98(9):e947-e957
pubmed: 34969939
Nat Commun. 2022 Sep 21;13(1):5308
pubmed: 36130946